Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8104793,bioavailability,Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,42,5513,DB00242,Cladribine
,8104793,bioavailability,Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,46,5514,DB00242,Cladribine
,8104793,maximum plasma concentration (Cmax),Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),nM,83,5515,DB00242,Cladribine
,8104793,maximum plasma concentration (Cmax),Food intake did not significantly influence the bioavailability of CdA (42% after food intake vs 46% while fasting) but it did reduce the maximum plasma concentration (Cmax) by 40%; 83 compared to 116 nM while fasting.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),nM,116,5516,DB00242,Cladribine
,8104793,time to reach maximum concentration (tmax),The time to reach maximum concentration (tmax) was delayed about 0.8 h after food intake.,On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),h,0.8,5517,DB00242,Cladribine
,8104793,bioavailability,"Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C. V. 0.26 with and C. V. 0.27 without).",On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,51,5518,DB00242,Cladribine
,8104793,bioavailability,"Pretreatment with omeprazole did not significantly influence the bioavailability of CdA (51% vs 46% without), or the interindividual variability in bioavailability in the fasting state (C. V. 0.26 with and C. V. 0.27 without).",On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104793/),%,46,5519,DB00242,Cladribine
,21599605,intracellular initial half-life,The intracellular initial half-life is 13 h and the terminal half-life is 30 h.,"Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599605/),h,13,8672,DB00242,Cladribine
,21599605,terminal half-life,The intracellular initial half-life is 13 h and the terminal half-life is 30 h.,"Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21599605/),h,30,8673,DB00242,Cladribine
,9533533,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),[μM] / [h·l],47,43981,DB00242,Cladribine
,9533533,AUC,"The area under the concentration versus time curve (AUC) of CdAMP in leukemia cells was generally higher (median, 47 micromol/liter x h) than the AUC of CdATP (median, 22 micromol/liter x h); however, in some patients (3 of 17), the reverse relationship was seen.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),[μM] / [h·l],22,43982,DB00242,Cladribine
,9533533,half-life (t(1/2)),"The median half-life (t(1/2)) of CdAMP was 15 h, and that of CdATP was 10 h.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,15,43983,DB00242,Cladribine
,9533533,half-life (t(1/2)),"The median half-life (t(1/2)) of CdAMP was 15 h, and that of CdATP was 10 h.",Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,10,43984,DB00242,Cladribine
,9533533,terminal t(1/2),The median terminal t(1/2) of CdA in plasma was 21 h.,Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533533/),h,21,43985,DB00242,Cladribine
,9255268,area under the concentration versus time curves,A pharmacokinetic analysis of the seven patients without leukemic cells showed that their area under the concentration versus time curves of plasma cladribine increased dose-dependently from 2661.3 +/- 300.4 nM x h at Level 1 (n = 3) to 3411.3 +/- 341.0 nM x h at Level 2 (n = 4) (P = 0.034).,Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255268/),h·nM,2661.3,44738,DB00242,Cladribine
,9255268,area under the concentration versus time curves,A pharmacokinetic analysis of the seven patients without leukemic cells showed that their area under the concentration versus time curves of plasma cladribine increased dose-dependently from 2661.3 +/- 300.4 nM x h at Level 1 (n = 3) to 3411.3 +/- 341.0 nM x h at Level 2 (n = 4) (P = 0.034).,Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255268/),h·nM,3411.3,44739,DB00242,Cladribine
,19326772,AUC,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),[h·μg] / [ml],0.66,44907,DB00242,Cladribine
,19326772,AUC,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),[h·μg] / [ml],1.2,44908,DB00242,Cladribine
,19326772,t1/2 beta,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),[h·μg] / [ml],1.2,44909,DB00242,Cladribine
,19326772,t1/2 beta,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),h,3.5,44910,DB00242,Cladribine
,19326772,t1/2 beta,"The AUC and t1/2 beta after a single 1 mg/kg ia and 2 mg/kg s.c. injection of CdA were 0.66 +/- 0.34 vs 1.2 +/- 0.3 microg x h/ml and 3.5 +/- 2.1 vs 4.5 +/- 2.2 h, respectively (p > 0.05).",Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),h,4.5,44911,DB00242,Cladribine
,19326772,absolute bioavailability,The mean absolute bioavailability following the s.c. injection was close to 90%.,Pharmacokinetics of cladribine in a rat model following subcutaneous and intra-arterial injections. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19326772/),%,90,44912,DB00242,Cladribine
,23777614,extraction recoveries,"The extraction recoveries were 85% for fludarabine and 95% for the internal standard, which represent a significant improvement over the previously published methods.",Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777614/),%,85,46188,DB00242,Cladribine
,23777614,extraction recoveries,"The extraction recoveries were 85% for fludarabine and 95% for the internal standard, which represent a significant improvement over the previously published methods.",Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777614/),%,95,46189,DB00242,Cladribine
,8823495,AUC,"The most important data points for estimation of the AUC were 2.5, 24, and 0.5 h after oral administration (AUC = 0.8630 x C0.5h + 4.2337 x C2.5h + 45.4364 x C24h) and 9, 1, and 16 h after s.c. injection (AUC = 1.8821 x C1h + 16.4256 x C9h + 25.4518 x C16h).","A limited sampling strategy for estimation of the cladribine plasma area under the concentration versus time curve after intermittent i.v. infusion, s.c. injection, and oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823495/),,1,52172,DB00242,Cladribine
,15183532,Excreted amount,Excreted amount of CAde in urine constituted about 1.1% after iv infusion and 4.7% after oral CdA treatment.,"Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15183532/),%,1.1,66653,DB00242,Cladribine
,15183532,Excreted amount,Excreted amount of CAde in urine constituted about 1.1% after iv infusion and 4.7% after oral CdA treatment.,"Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemia. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15183532/),%,4.7,66654,DB00242,Cladribine
,17706181,flow rate,"The system was operated at ambient temperature with a flow rate of 0.3 mL/min, and UV wavelength at 265 nm, and an operating pressure of ca. 1.56 kpsi.",Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706181/),[ml] / [min],0.3,69932,DB00242,Cladribine
,17706181,retention times,"Under these conditions, the average retention times of CdA and AZT were 13.5 and 21 min, respectively, and recoveries were between 80 - 95%.",Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706181/),min,13.5,69933,DB00242,Cladribine
,17706181,retention times,"Under these conditions, the average retention times of CdA and AZT were 13.5 and 21 min, respectively, and recoveries were between 80 - 95%.",Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706181/),min,21,69934,DB00242,Cladribine
,17706181,recoveries,"Under these conditions, the average retention times of CdA and AZT were 13.5 and 21 min, respectively, and recoveries were between 80 - 95%.",Development and validation of a sensitive and specific HPLC assay of cladribine for pharmacokinetics studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706181/),%,80 - 95,69935,DB00242,Cladribine
,19907111,duration of response,"The median duration of response was 20+ and 21+ months for CR, and 12 months ranging from 3 to 34 months for PR, respectively.",Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19907111/),month,20,71850,DB00242,Cladribine
,19907111,duration of response,"The median duration of response was 20+ and 21+ months for CR, and 12 months ranging from 3 to 34 months for PR, respectively.",Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19907111/),month,21,71851,DB00242,Cladribine
,19907111,duration of response,"The median duration of response was 20+ and 21+ months for CR, and 12 months ranging from 3 to 34 months for PR, respectively.",Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19907111/),month,12,71852,DB00242,Cladribine
,12439044,clearance rate,"The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m for the first 3 days of 2-CdA therapy.",Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439044/),[l] / [h·m],12.4,74076,DB00242,Cladribine
,7850921,plasma concentrations at steady-state (Cpss),Average plasma concentrations at steady-state (Cpss) ranged from 3 ng/ml at the initial dose level to 13 ng/ml at the dose level of 8.1 mg/m2 per day.,A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850921/),[ng] / [ml],3,74206,DB00242,Cladribine
,7850921,plasma concentrations at steady-state (Cpss),Average plasma concentrations at steady-state (Cpss) ranged from 3 ng/ml at the initial dose level to 13 ng/ml at the dose level of 8.1 mg/m2 per day.,A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850921/),[ng] / [ml],13,74207,DB00242,Cladribine
,7850921,maximum tolerated dose,The maximum tolerated dose for 2-CdA given by 5-day continuous infusion was 8.1 mg/m2 per day in this study.,A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850921/),mg,8,74208,DB00242,Cladribine
,9598154,terminal half life (t1/2),The median terminal half life (t1/2) of CdA in plasma was 21.1 h and the area under the curve (AUC) was median 1.2 microMh.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),h,21.1,74598,DB00242,Cladribine
,9598154,area under the curve (AUC),The median terminal half life (t1/2) of CdA in plasma was 21.1 h and the area under the curve (AUC) was median 1.2 microMh.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),μMh,1.2,74599,DB00242,Cladribine
,9598154,t1/2,The median t1/2 was 14.6 h for CdAMP and 9.7 h for CdATP.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),h,14.6,74600,DB00242,Cladribine
,9598154,t1/2,The median t1/2 was 14.6 h for CdAMP and 9.7 h for CdATP.,"Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9598154/),h,9.7,74601,DB00242,Cladribine
,15757511,Clearance,"Clearance was found to be 39.3 L/hour, with a large interindividual variability.",Application of population pharmacokinetics to cladribine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757511/),[l] / [h],39.3,77590,DB00242,Cladribine
,15757511,half-life,The half-life for the terminal phase was 16 hours.,Application of population pharmacokinetics to cladribine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757511/),h,16,77591,DB00242,Cladribine
,15757511,Bioavailability,"Bioavailability was 100% and 35% for subcutaneous and oral administration, respectively, with low interindividual variability.",Application of population pharmacokinetics to cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757511/),%,100,77592,DB00242,Cladribine
,15757511,Bioavailability,"Bioavailability was 100% and 35% for subcutaneous and oral administration, respectively, with low interindividual variability.",Application of population pharmacokinetics to cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15757511/),%,35,77593,DB00242,Cladribine
,22658903,AUC,"Under the proposed approach, the topotecan dosing was selected so as to achieve the final AUC value of 140±20 ng/ml h.",Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22658903/),[ng] / [h·ml],140,81265,DB00242,Cladribine
,15571270,maximum tolerated dose (MTD),Phase I studies among 32 patients with acute leukemia defined a maximum tolerated dose (MTD) of 40 mg/m2/d given as a one hour infusion daily for 5 days.,Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15571270/),[mg] / [d·m2],40,95777,DB00242,Cladribine
,15571270,overall response rate,"Twenty patients (32%) achieved complete response (CR), 1 had a partial response (PR), and 9 had a CR but without platelet recovery (CRp), for an overall response rate of 48%.",Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15571270/),%,48,95778,DB00242,Cladribine
,19432900,overall response rate,"The overall response rate was 50% (9/18; 80% confidence interval, 35-65%), with 11% (2/18) complete response.",Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19432900/),%,50,115476,DB00242,Cladribine
,19432900,time to progression,"With a median follow-up of 296 days, the estimated median time to progression for 18 eligible patients was 382 days.",Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19432900/),d,382,115477,DB00242,Cladribine
,7974633,Recoveries,"Recoveries of CdA and CAde at 100 nmol/L were 90.6 +/- 4.9 and 98.7 +/- 7.8%, respectively.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),%,90.6,117141,DB00242,Cladribine
,7974633,Recoveries,"Recoveries of CdA and CAde at 100 nmol/L were 90.6 +/- 4.9 and 98.7 +/- 7.8%, respectively.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),%,98.7,117142,DB00242,Cladribine
,7974633,Recovery,Recovery of IS was 96.1 +/- 6.1% at 250 nmol/l.,Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),%,96.1,117143,DB00242,Cladribine
,7974633,limits of detection,"In plasma, limits of detection of CdA and CAde were 1 and 2 nmol/L, respectively.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),[nM] / [l],1,117144,DB00242,Cladribine
,7974633,limits of detection,"In plasma, limits of detection of CdA and CAde were 1 and 2 nmol/L, respectively.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),[nM] / [l],2,117145,DB00242,Cladribine
,7974633,limit of detection,"In urine, the limit of detection was 100 nmol/L for both compounds.",Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7974633/),[nM] / [l],100,117146,DB00242,Cladribine
,7906999,clearance,The mean (SD) clearance was 39.4 (12.4) liters/h/m2 and ranged from 14.4-55.4 liters/h/m2.,Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),[l] / [h·m2],39.4,119294,DB00242,Cladribine
,7906999,steady-state plasma concentration,The mean (SD) steady-state plasma concentration (predicted 120-h concentration) was 37.7 (17.3) nM and ranged from 23.2-84.5 nM.,Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),nM,37.7,119295,DB00242,Cladribine
,7906999,steady-state plasma concentration,The mean (SD) steady-state plasma concentration (predicted 120-h concentration) was 37.7 (17.3) nM and ranged from 23.2-84.5 nM.,Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),nM,23.2-84.5,119296,DB00242,Cladribine
,7906999,terminal phase half-life,"The terminal phase half-life in 22 patients ranged from 14.3-25.8 h, with a mean (SD) of 19.7 (3.4) h.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),h,14.3-25.8,119297,DB00242,Cladribine
,7906999,terminal phase half-life,"The terminal phase half-life in 22 patients ranged from 14.3-25.8 h, with a mean (SD) of 19.7 (3.4) h.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),h,19.7,119298,DB00242,Cladribine
,7906999,volume of distribution at steady state,"The volume of distribution at steady state was highly variable, with a mean (SD) of 356.6 (225.2) liters/m2.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),[l] / [m2],356.6,119299,DB00242,Cladribine
,7906999,Renal clearance,"Renal clearance was determined in 7 patients and ranged from 34.6-643.6 ml/min/m2, with a mean (SD) of 317.9 (208.7) ml/min/m2.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),[ml] / [m2·min],34.6-643.6,119300,DB00242,Cladribine
,7906999,Renal clearance,"Renal clearance was determined in 7 patients and ranged from 34.6-643.6 ml/min/m2, with a mean (SD) of 317.9 (208.7) ml/min/m2.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),[ml] / [m2·min],317.9,119301,DB00242,Cladribine
,7906999,cerebrospinal fluid concentration,"In 11 patients, the mean (SD) cerebrospinal fluid concentration was 6.1 (3.97) nM, a mean of 18.2% of the steady-state plasma concentration.",Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7906999/),n,6,119302,DB00242,Cladribine
,9068927,oral bioavailability,"The oral bioavailability of cladribine is 37 to 51%, and that of subcutaneous administration is 100%.",The clinical pharmacokinetics of cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),%,37 to 51,143470,DB00242,Cladribine
,9068927,oral bioavailability,"The oral bioavailability of cladribine is 37 to 51%, and that of subcutaneous administration is 100%.",The clinical pharmacokinetics of cladribine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),%,100,143471,DB00242,Cladribine
,9068927,terminal half-life,The terminal half-life varies from 5.7 to 19.7 hours and the apparent volume of distribution from 54 to 357 L/m2.,The clinical pharmacokinetics of cladribine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),h,5.7 to 19.7,143472,DB00242,Cladribine
,9068927,apparent volume of distribution,The terminal half-life varies from 5.7 to 19.7 hours and the apparent volume of distribution from 54 to 357 L/m2.,The clinical pharmacokinetics of cladribine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),[l] / [m2],54 to 357,143473,DB00242,Cladribine
,9068927,half-lives,The intracellular concentration of these metabolites is several hundred-fold higher than that of cladribine in plasma and they are retained in leukaemia cells with half-lives between 9 and > 30 hours depending on diagnosis and sampling schedule.,The clinical pharmacokinetics of cladribine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068927/),h,9 and > 30,143474,DB00242,Cladribine
,1346800,total response rate,"Eight (47%) of the 17 patients with AML had complete hematologic remissions (four after the initial course of 2-CDA), and two (12%) had partial remissions, for a total response rate of 59%.",2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346800/),%,59,145745,DB00242,Cladribine
,1346800,times to recovery,"In responding patients, the median times to recovery of neutrophil counts greater than 0.5 x 10(9)/L and platelet counts greater than 50 x 10(9)/L were 18 and 21 days, respectively.",2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346800/),d,18,145746,DB00242,Cladribine
,1346800,times to recovery,"In responding patients, the median times to recovery of neutrophil counts greater than 0.5 x 10(9)/L and platelet counts greater than 50 x 10(9)/L were 18 and 21 days, respectively.",2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346800/),d,21,145747,DB00242,Cladribine
,1346800,steady-state plasma concentration,"The mean steady-state plasma concentration of 2-CDA was 34.6 nmol/L (range, 20 to 54 nmol/L).",2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1346800/),[nM] / [l],34.6,145748,DB00242,Cladribine
,8622049,F,"The F value of oral 2-CdA measured on days 1 and 5 was 37.2% and 36.7%, respectively.",Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622049/),%,37.2,156078,DB00242,Cladribine
,8622049,F,"The F value of oral 2-CdA measured on days 1 and 5 was 37.2% and 36.7%, respectively.",Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622049/),%,36.7,156079,DB00242,Cladribine
,8622049,F,The F value of 2-CdA after oral administration was approximately 37% and there were no cumulative differences in bioavailability observed on multiple dosing of the drug.,Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622049/),%,37,156080,DB00242,Cladribine
,10912576,"rate of elimination, k(elim)","The calculated rate of elimination, k(elim), averaged 0.336 h(-1) with s.c. and 0.397 h(-1) with i.v. administration.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),1/[h],0.336,161302,DB00242,Cladribine
,10912576,"rate of elimination, k(elim)","The calculated rate of elimination, k(elim), averaged 0.336 h(-1) with s.c. and 0.397 h(-1) with i.v. administration.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),1/[h],0.397,161303,DB00242,Cladribine
,10912576,volumes of distribution,The estimated volumes of distribution were 1.67 and 1.58 l/kg.,Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[l] / [kg],1.67,161304,DB00242,Cladribine
,10912576,volumes of distribution,The estimated volumes of distribution were 1.67 and 1.58 l/kg.,Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[l] / [kg],1.58,161305,DB00242,Cladribine
,10912576,areas under the concentration time curves,"The areas under the concentration time curves (608 +/- 65 pmol x h/ml after s.c. administration vs 571 +/- 50 pmol x h/ml during i.v. infusion) and the urinary excretion of 2-CDA in 24 h (4.75 +/- 0.95 vs 3.55 +/- 0.53 micromol/24 h) were similar in both groups, indicating identical bioavailability.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[h·pM] / [ml],608,161306,DB00242,Cladribine
,10912576,areas under the concentration time curves,"The areas under the concentration time curves (608 +/- 65 pmol x h/ml after s.c. administration vs 571 +/- 50 pmol x h/ml during i.v. infusion) and the urinary excretion of 2-CDA in 24 h (4.75 +/- 0.95 vs 3.55 +/- 0.53 micromol/24 h) were similar in both groups, indicating identical bioavailability.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[h·pM] / [ml],571,161307,DB00242,Cladribine
,10912576,urinary excretion,"The areas under the concentration time curves (608 +/- 65 pmol x h/ml after s.c. administration vs 571 +/- 50 pmol x h/ml during i.v. infusion) and the urinary excretion of 2-CDA in 24 h (4.75 +/- 0.95 vs 3.55 +/- 0.53 micromol/24 h) were similar in both groups, indicating identical bioavailability.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[μM] / [24·h],4.75,161308,DB00242,Cladribine
,10912576,urinary excretion,"The areas under the concentration time curves (608 +/- 65 pmol x h/ml after s.c. administration vs 571 +/- 50 pmol x h/ml during i.v. infusion) and the urinary excretion of 2-CDA in 24 h (4.75 +/- 0.95 vs 3.55 +/- 0.53 micromol/24 h) were similar in both groups, indicating identical bioavailability.",Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10912576/),[μM] / [24·h],3.55,161309,DB00242,Cladribine
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,102,179814,DB00242,Cladribine
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,19,179815,DB00242,Cladribine
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,24,179816,DB00242,Cladribine
,1357107,bioavailability,"The bioavailability of SC CdA was 102% +/- 28% (mean +/- SD), and the bioavailability of CdA administered in enteric-coated capsules was 19%, 24%, and 60%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,60,179817,DB00242,Cladribine
,1357107,bioavailability,"In the three patients who were given 0.14 mg/kg orally dissolved in PBS, the bioavailability was 48% +/- 8%, whereas in the seven patients who received 0.28 mg/kg, the bioavailability was 55% +/- 17%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,48,179818,DB00242,Cladribine
,1357107,bioavailability,"In the three patients who were given 0.14 mg/kg orally dissolved in PBS, the bioavailability was 48% +/- 8%, whereas in the seven patients who received 0.28 mg/kg, the bioavailability was 55% +/- 17%.",On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1357107/),%,55,179819,DB00242,Cladribine
,7503639,bioavailability,"Recently, however, pharmacokinetic studies have shown that the bioavailability of oral CdA is 50% and of s.c. injection 100%.","2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7503639/),%,50,195364,DB00242,Cladribine
,7503639,bioavailability,"Recently, however, pharmacokinetic studies have shown that the bioavailability of oral CdA is 50% and of s.c. injection 100%.","2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7503639/),%,100,195365,DB00242,Cladribine
,7564508,half-life of the initial phase,"In the present study, time-courses of 2-CdA loss from CLL cells were biexponential: the mean half-life of the initial phase was 0.30 +/- 0.18 h; the presence of 0.5 microM nitrobenzylthioinosine (NBMPR, a classical inhibitor of nucleoside transport) in the suspending medium, significantly decreased the initial rate of 2-CdA efflux (mean half-life, 0.43 +/- 0.22 h).",Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564508/),h,0.30,225139,DB00242,Cladribine
,7564508,half-life,"In the present study, time-courses of 2-CdA loss from CLL cells were biexponential: the mean half-life of the initial phase was 0.30 +/- 0.18 h; the presence of 0.5 microM nitrobenzylthioinosine (NBMPR, a classical inhibitor of nucleoside transport) in the suspending medium, significantly decreased the initial rate of 2-CdA efflux (mean half-life, 0.43 +/- 0.22 h).",Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564508/),h,0.43,225140,DB00242,Cladribine
,7564508,AUCs,"As a consequence, AUCs (areas under time-course plots) were significantly higher in the NBMPR-treated cells (4.56 +/- 2.01 pmol.h/10(6) cells, n = 19) than in untreated control cells (3.83 +/- 1.74 pmol.h/10(6) cells; n = 19).",Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564508/),[h·pM] / [10(6)·cells],4.56,225141,DB00242,Cladribine
,7564508,AUCs,"As a consequence, AUCs (areas under time-course plots) were significantly higher in the NBMPR-treated cells (4.56 +/- 2.01 pmol.h/10(6) cells, n = 19) than in untreated control cells (3.83 +/- 1.74 pmol.h/10(6) cells; n = 19).",Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7564508/),[h·pM] / [10(6)·cells],3.83,225142,DB00242,Cladribine
,9375754,response rate,Clinical trials with intravenous cladribine infusions in pretreated patients with Waldenström's macroglobulinaemia have shown a response rate of 40%.,Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9375754/),%,40,230529,DB00242,Cladribine
,9375754,Overall response rate,Overall response rate including disease stabilization which had been progressive under previous therapy was 68%.,Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9375754/),%,68,230530,DB00242,Cladribine
,9375754,time to treatment failure,"Median time to treatment failure and remission duration were 4.4 (range 0.5-33) and 8 months (5-29), respectively.",Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9375754/),,4.4,230531,DB00242,Cladribine
,9375754,remission duration,"Median time to treatment failure and remission duration were 4.4 (range 0.5-33) and 8 months (5-29), respectively.",Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9375754/),month,8,230532,DB00242,Cladribine
,1680554,alpha-,"The plasma concentration data from individual patients were fitted to a two-compartment model with alpha- and beta-half-lives of 35 +/- 12 (mean +/- SD) min and 6.7 +/- 2.5 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),min,35,239878,DB00242,Cladribine
,1680554,beta-half-lives,"The plasma concentration data from individual patients were fitted to a two-compartment model with alpha- and beta-half-lives of 35 +/- 12 (mean +/- SD) min and 6.7 +/- 2.5 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h,6.7,239879,DB00242,Cladribine
,1680554,volume of distribution,The volume of distribution was 9.2 +/- 5.4 liters/kg.,On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),[l] / [kg],9.2,239880,DB00242,Cladribine
,1680554,steady-state concentration,The steady-state concentration of CdA during the 24-h infusion was 22.5 +/- 11.1 nM.,On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),nM,22.5,239881,DB00242,Cladribine
,1680554,areas under the time versus concentration curves,"The areas under the time versus concentration curves were 552 +/- 258 and 588 +/- 185 nM x h, respectively, for the 24- and 2-h infusions.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h·nM,552,239882,DB00242,Cladribine
,1680554,areas under the time versus concentration curves,"The areas under the time versus concentration curves were 552 +/- 258 and 588 +/- 185 nM x h, respectively, for the 24- and 2-h infusions.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h·nM,588,239883,DB00242,Cladribine
,1680554,half-lives,"When the mean plasma concentrations of the 12 patients were fitted to a 3-compartment model, the half-lives of the alpha-, beta-, and tau-phases were 8 min, 1 h 6 min, and 6.3 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),min,8,239884,DB00242,Cladribine
,1680554,half-lives,"When the mean plasma concentrations of the 12 patients were fitted to a 3-compartment model, the half-lives of the alpha-, beta-, and tau-phases were 8 min, 1 h 6 min, and 6.3 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h,1,239885,DB00242,Cladribine
,1680554,half-lives,"When the mean plasma concentrations of the 12 patients were fitted to a 3-compartment model, the half-lives of the alpha-, beta-, and tau-phases were 8 min, 1 h 6 min, and 6.3 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),min,6,239886,DB00242,Cladribine
,1680554,half-lives,"When the mean plasma concentrations of the 12 patients were fitted to a 3-compartment model, the half-lives of the alpha-, beta-, and tau-phases were 8 min, 1 h 6 min, and 6.3 h, respectively.",On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1680554/),h,6.3,239887,DB00242,Cladribine
